[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457058":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":64,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":10,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Sheffield Teaching Hospitals NHS Foundation Trust","OTHER",[8,13,16,19,22,25],{"label":9,"type":10,"description":10,"interventionNames":11},"Bladder Cancer",null,[12],"Diagnostic Test: Functional drug screen",{"label":14,"type":10,"description":10,"interventionNames":15},"Kidney Cancer",[12],{"label":17,"type":10,"description":10,"interventionNames":18},"Melanoma",[12],{"label":20,"type":10,"description":10,"interventionNames":21},"Sarcoma",[12],{"label":23,"type":10,"description":10,"interventionNames":24},"Glioblastoma",[12],{"label":26,"type":10,"description":10,"interventionNames":27},"Head and Neck Cancer",[12],[29],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"DIAGNOSTIC_TEST","Functional drug screen","High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity \u002F resistance profiles",[9,23,26,14,17,20],[35],{"name":36,"affiliation":37,"role":38},"Sarah Danson, PhD, FRCP","University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":44},"Greg Wells, PhD","CONTACT","+44 114 215 9098","g.wells@sheffield.ac.uk",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Sheffield","South Yorkshire","S10 2JF","United Kingdom","UK",{"type":54,"coordinates":55},"Point",[56,57],-1.4659,53.38297,{"lat":57,"lon":56},[60],{"name":61,"role":42,"phone":62,"phoneExt":10,"email":63},"Dipak Patel, PhD","+44 114 226 5941","dipak.patel12@nhs.net",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[67],{"name":68,"class":6},"University of Sheffield","100457058","ex-vivo-determined-cancer-therapy-100457058",false,"NCT05231655","Ex VIvo DEtermiNed Cancer Therapy","Ex Vivo Multi Drug Screening of Solid Tumours to Determine Personalised Therapy Efficacy and Resistance","EVIDENT","Inclusion Criteria:\n\n\\>16 years of age with a diagnosis of known or suspected solid cancer who will undergo surgery, biopsy, aspirate, or TURBT\n\nWilling to donate a section fresh tumour tissue from surgery, a TURBT, fluid aspirate, or biopsy surplus to diagnostic use\n\nWilling to donate a 9ml blood sample\n\nAble to give written informed consent\n\nPreviously treated patients are eligible if:\n\n* Present with a recurrence of a previously treated tumour. This may be a local or metastatic recurrence\n* Have undergone treatment for their cancer, but fail to respond to this and progress\n* Have received neoadjuvant therapy for their tumour\n* Have undergone chemotherapy, targeted therapy, immunotherapy, hormone therapy and or radiotherapy for a previous tumour\n\nExclusion Criteria:\n\nPatients with a known diagnosis of a blood borne virus (Hepatitis B, Hepatitis C, HIV). (The laboratories where experiments will be conducted do not have the safety facilities to use material containing these pathogens)\n\nPatients with a current positive COVID-19 infection","ALL","16 Years",{"count":80,"type":81},600,"ESTIMATED","OBSERVATIONAL","EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.",[9,14,17,20,23,26],[86,87,88],"Personalized medicine","Ex vivo drug screen","Image based analysis","2025-02-20",{"date":91,"type":92},"2025-02-24","ACTUAL",{"date":94,"type":92},"2021-07-07",{"date":96,"type":81},"2027-01",{"name":5,"class":6},1]